Investigational drug · Phase 3
HS-10370
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Carcinoma, Non-Small-Cell Lung.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "HS-10370"
First trial start
2026
Oct 31, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-10370", any sponsor or status.
Conditions studied
As listed on its trial records.
- Carcinoma, Non-Small-Cell Lung
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-10370" as an intervention, largest first.
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid TumorsNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06963502 · 762 participants (planned) · Start May 30, 2025 · Primary completion Dec 31, 2028
Drug: HS-10370; HS-20117 and 6 more · For: Advanced Solid Tumors; Colorectal Cancer; Non-Small Cell Lung Cancer
Sites: Hangzhou, China; Shanghai, China
- A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerPivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07822542 · 448 participants (planned) · Start Oct 31, 2026 · Primary completion May 31, 2030
Drug: HS-10370; Adebrelimab and 4 more · For: Carcinoma, Non-Small-Cell Lung
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid TumorsNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06594874 · 350 participants (planned) · Start Oct 31, 2024 · Primary completion Oct 31, 2026
Drug: HS-10370; Adebrelimab and 3 more · For: Non-Small Cell Lung Cancer; Advanced Solid Tumors
Sites: Wuhan, China
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT05367778 · 176 participants (planned) · Start Jun 3, 2022 · Primary completion Apr 30, 2025
Drug: HS-10370 · For: Advanced Solid Tumor
Sites: Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Carcinoma, Non-Small-Cell Lung
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- OleclumabMEDI9447Phase 37 trials
AstraZeneca · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Metastatic Microsatellite-stable Colorectal Cancer
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- NavlimetostatBMS-986504, MRTX1719Phase 34 trials
Bristol Myers Squibb · Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors
- Sigvotatug VedotinSGN-B6A, PF-08046047Phase 33 trials
Pfizer · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.